{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"10.5","value":"3.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"2.8","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"24.7","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"14.8","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Rate of complete response is the proportion of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR will be determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown\" will be treated as non responders","dispersionType":"95% Confidence Interval","groups":[{"description":"The efficacy and safety of LDE225 200mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG000","title":"LDE225 200mg laBCC"},{"description":"The efficacy and safety of LDE225 800mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG001","title":"LDE225 800mg laBCC"},{"description":"The efficacy and safety of LDE225 200mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG002","title":"LDE225 200mg mBCC"},{"description":"The efficacy and safety of LDE225 800mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG003","title":"LDE225 800mg mBCC"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Complete Response Rate (CRR) Per Central Review (FAS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}